Before receiving immune checkpoint inhibitor therapy, NKTCL patients could be analyzed for PD-L1 mutations and a TCR sequence to avoid economic excess and minimize adverse events. The gene discussed is CD274; the disease is extranodal nasal NK/T cell lymphoma.